Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $114.86 +2.73%
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +54.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 GAAP EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $23.8 million versus the consensus estimate of $23.46 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $115-125 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McDonald’s said to plan value strategy overhaul to revive US sales growth
- Gartner places F5 in AI application security emerging market report
- Investec Double Upgrades Supreme Industries (SI:IN) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
